Clinical Trial

Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels

Study acronym: VINCENT
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this open label 16 week trial is to evaluate Lp(a) levels for patients with elevated Lp(a) being treated with obicetrapib and obiceptrapib/evolocumab Patients will: Have baseline Lp(a) tested at randomization Take 10mg/dL obiceptrapib daily for 8 weeks and have Lp(a) tested at Week 8 Take 10 mg/dL obicetrapib daily/evolocumab 140 every other week for 8 weeks and have Lp(a) retested at Week 16
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-07-03; most recent amendment 2026-04-06.
Status change: Not Yet Recruiting → Recruiting 2024-11-12
Trial Details
NCT Number NCT06496243
Lead Sponsor NewAmsterdam Pharma
Conditions Dyslipidemias
Enrollment 69 participants
Start Date 2024-12-02
Primary Completion 2026-11 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2026-04-09